Maze Therapeutics

Company snapshot

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 60 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Maze Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Maze Therapeutics.

1. Jun 8, 2026 Clinical update

   NGAM-13 — Phase 3

2. Jun 8, 2026 Clinical update

   NGAM-12 — Phase 3

3. Jun 8, 2026 Clinical update

   CONE-02 — Phase 3

4. Jun 8, 2026 Clinical update

   NGAM-16 — Phase 3

5. Jun 5, 2026 Clinical update

   Newnorm — Phase 3

View all clinical trial activity →

• What is Maze Therapeutics?

  Maze Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker MAZE. Primary therapeutic focus areas include Pediatric acute-onset neuropsychiatric syndrome (PANS), acute hereditary angioedema attacks, APOL1 Kidney Disease (A

• Is Maze Therapeutics publicly traded?

  Yes. Maze Therapeutics is listed with ticker MAZE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Maze Therapeutics develop or market?

  We link 12 drug profile(s) where Maze Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/maze-therapeutics#company-drugs.

• What are the latest developments for Maze Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Maze Therapeutics focus on?

  Maze Therapeutics focuses on Pediatric acute-onset neuropsychiatric syndrome (PANS), acute hereditary angioedema attacks, APOL1 Kidney Disease (AKD) based on our analysis of their pipeline programs and drug development activities.